Influx Healthtech
SMENSE: INFLUX
₹ 274.95▲ 21.1 (+8.31%)28 Oct, 03:29 pm IST
- Market cap
- ₹ 595 Cr.
- P/E
- 32.7x
- P/B
- 5.93x
- 52-week range
- 169 – 315
- ROE
- 30%
- ROCE
- 40%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Influx Healthtech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)32.7 against a typical 34.3: cheaper than most peers (1st = cheapest).105th of 220
- Share price, 3 months−7.4% against a typical −0.5%.136th of 200
- Size₹ 595 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).98th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 20 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 48 | 57 | 67 | 80 |
| Expenses | 39 | 45 | 52 | 65 |
| Operating Profit | 9 | 11 | 15 | 15 |
| OPM % | 19% | 20% | 22% | 19% |
| Other Income | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 |
| Profit before tax | 8 | 10 | 13 | 14 |
| Tax % | 27% | 24% | 23% | 25% |
| Net Profit | 6 | 8 | 10 | 11 |
| EPS in Rs | 3.1 | 4.21 | 4.32 | 4.56 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 25%
- TTM
- 40%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 42%
- TTM
- 54%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
Return on Equity
- 10 Years
- —
- 5 Years
- 45%
- 3 Years
- 39%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 32.7xEPS (12 months) ₹ 8.26Median P/E 31.8x
P/E (times)EPS (₹)
Prices are delayed and for information only. Nothing on this page is investment advice.